Key result
DCB therapy is consistently linked to favorable coronary plaque modification over stents in ACS.
Why the study?
Does drug-coated balloon therapy favorably modify coronary plaque morphology and composition in patients presenting with acute coronary syndrome?
Systematic Review (n=446)
Does drug-coated balloon therapy favorably modify coronary plaque morphology and composition in patients presenting with acute coronary syndrome?
Answers are grounded in this paper and cite their sources.
This systematic review suggests that paclitaxel-coated balloon therapy in acute coronary syndrome is associated with favorable plaque regression, reduced lipid core burden, and luminal enlargement, supporting its potential role as a stent-free revascularization strategy.
Background: In the treatment of diseased coronary arteries, drug-coated balloons (DCBs) have emerged as a "leave nothing behind" alternative to drug-eluting stents, yet their effects on coronary plaque morphology in Acute Coronary Syndromes (ACS) are not well characterised. This systematic review evaluates the impact of DCB therapy on plaque morphology in patients presenting with ACS. Method: A systematic search of PubMed, Cochrane Library, Scopus, and ScienceDirect identified studies reporting plaque-related outcomes following DCB treatment in adult patients with ACS. Six studies met the inclusion criteria, incorporating intravascular ultrasound (IVUS), optical coherence tomography (OCT), near-infrared spectroscopy (NIRS) or angiographic assessments of plaque burden, plaque volume, plaque area, lipid burden, or calcification. Results: Across comparative and non-comparative studies, DCB therapy was consistently associated with favourable imaging changes, including reductions in plaque area, plaque burden, or plaque atheroma volume, and increased lumen dimensions. In studies assessing compositional characteristics, DCB therapy was linked with reductions in lipid core burden and lower calcification scores compared with stent-based strategies. However, heterogeneity in study design, imaging methods, and outcome reporting limits direct comparison between studies, and causality cannot be conclusively inferred. Conclusion: Available evidence suggests that DCB therapy may favourably modify plaque morphology in ACS, influencing plaque size and composition. The potential for DCBs to promote plaque regression, reduce lipid burden, and facilitate positive vascular remodelling warrants further investigation in larger, dedicated ACS cohorts. Future studies integrating advanced imaging and molecular profiling may clarify mechanistic pathways and identify patient groups most likely to benefit from DCB-based strategies.
No takes yet. Share an insight, caveat, or question.
Harihararajah et al. (2026) conducted a systematic review in Acute coronary syndrome (STEMI, NSTEMI, or unstable angina) and coronary artery disease (n=446). Drug-coated balloon (DCB) therapy (paclitaxel-coated balloons including SeQuent Please, SeQuent Please NEO, Bingo, and Ryusei) vs. Drug-eluting stents (DES), bailout stenting, stable angina comparators, or none (single-arm studies) was evaluated on Coronary plaque morphology (plaque burden, plaque volume, plaque area, lipid core burden, calcification score, and lumen dimensions) assessed by IVUS, OCT, or NIRS. Drug-coated balloon therapy was consistently associated with favorable plaque modification in ACS across 6 studies, including reduced plaque area, burden, lipid core, and late lumen loss vs stents.
Synapse has enriched 10 related papers. Consider them for comparative context: